A nationwide survey of MYH9-related disease in Japan

• Published in: Clinical and experimental nephrology Vol. 28; no. 1; pp. 40 - 49
• Main Authors: Shirai, Yoko, Miura, Kenichiro, Hamada, Riku, Ishikura, Kenji, Kunishima, Shinji, Hattori, Motoshi
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.01.2024; Springer Nature B.V
• Subjects: Angiotensin; Bleeding; End-stage renal disease; Genetic analysis; Hemodialysis; Kidney diseases; Kidney transplantation; Leukocytes (granulocytic); Medicine; Medicine & Public Health; Myosin; Nephrology; Nephropathy; Original Article; Patients; Peritoneal dialysis; Renin; Surveys; Urology; Japan; related disease; Kidney replacement therapy; Bleeding complications; Renin-angiotensin system inhibitors; Epstein syndrome; MYH9-related disease
• ISSN: 1342-1751; 1437-7799; 1437-7799
• DOI: 10.1007/s10157-023-02404-3

Background MYH9 -related disease ( MYH9 -RD) is characterized by congenital macrothrombocytopenia, Döhle body-like granulocyte inclusions, and nephropathy, which may progress to end-stage kidney disease (ESKD). However, information on the effects of renin-angiotensin system (RAS) inhibitors on kidney survival is currently lacking and the outcomes of kidney replacement therapy (KRT) in MYH9 -RD are largely unknown. Methods We conducted a cross-sectional nationwide survey by sending questionnaires to 145 institutions in Japan and analyzed data for 49 patients. Results The median patient age was 27 years. Genetic analysis was performed in 37 (76%) patients. Twenty-four patients (65%) had MYH9 variants affecting the motor domain of non-muscle myosin heavy chain-IIA, and these patients had poorer kidney survival than those with variants affecting the tail domain ( P  = 0.02). There was no significant difference in kidney survival between patients treated with and without RAS inhibitors. Hemodialysis and peritoneal dialysis were performed in 16 and 7 patients, respectively. There were no major bleeding complications during the perioperative period or during follow-up, except for one patient. Most of the 11 patients who underwent kidney transplantation required perioperative red cell concentrate transfusions, but there was no graft loss during the median posttransplant observational period of 2.0 (interquartile range, 1.3–6.8) years. Conclusion Our study demonstrated no beneficial effect of RAS inhibitors on kidney function in patients with MYH9 -RD, indicating the need for further studies with more patients. All modalities of KRT are feasible options for MYH9 -RD patients who progress to ESKD, with adequate attention to bleeding complications.